A Study of Viracept in HIV-Positive Women

Agouron Pharmaceuticals

Status and phase: Completed; Phase 2

Conditions: HIV Infections

Treatments: Drug: Nelfinavir mesylate

Study type: Interventional

Funder types: Industry

Identifiers

NCT00002171

AG1343 - 534

Study 534

259D

Details and patient eligibility

About

The purpose of this study is to see if it is safe and effective to give Viracept plus stavudine (d4T) plus lamivudine (3TC) to HIV-positive women with a CD4 count <= 400 cells/mm3. This study also examines how the body handles Viracept when given with d4T and 3TC.

Sex: Female

Ages: 13+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria

Patients must have:

• HIV infection.
• CD4 T cell count <= 400 cells/mm3.

Exclusion Criteria

Prior Medication:

Excluded:

• Prior therapy or less than 1 month of therapy with d4T and/or 3TC.
• Prior protease inhibitor therapy.